Guide

Switching from Ozempic to Zepbound: how it actually works

The head-to-head trial made this the most asked switch in the category. Here is what the data supports, what has no official answer, and what the switch weeks tend to feel like while one ladder fades and the other climbs.

MedicationSURMOUNT-5: the head-to-head trial, cited belowUpdated September 2026

Why this switch became the question

In 2025 the comparison stopped being indirect: SURMOUNT-5 put tirzepatide and semaglutide head to head for 72 weeks in adults with elevated weight and no diabetes, each titrated to the highest tolerated dose. Tirzepatide averaged 20.2% weight loss against semaglutide's 13.7%, and waist reduction favored it too. That result, plus formulary churn and price programs, is why prescribers now field this question weekly. The full comparison across every drug in the class lives in the comparison tool.

The honest counterweight: an average is not a prediction. Semaglutide responders exist in large numbers, the semaglutide arm still lost a life-changing amount, and the trial compared maximum tolerated doses, not your dose. Which is why the real question is not "which drug is better" but "is there a reason for me to move."

The three legitimate reasons to switch

  • A true stall at the top of the ladder. If you are at 2 mg Ozempic or 2.4 mg Wegovy, genuinely plateaued short of your goal, and the plateau guide's energy-balance explanation does not account for it, the different receptor profile is the remaining lever.
  • Tolerability. Some people who struggle on one molecule do better on the other, in both directions. This is reported pattern, not trial-proven, but it is a common prescriber rationale.
  • Coverage and cost. The least medical and most common reason: the formulary changed, the deductible reset, the savings program ended. If that is the trigger, read the affordability guide first; switching molecules is only one of the moves available.

The dose question nobody can shortcut

There is no conversion table, and that is not the labels being lazy. Semaglutide works one receptor; tirzepatide works two. Milligrams of one are not units of the other, so the Zepbound label starts everyone at 2.5 mg and climbs by tolerability, regardless of what you took before. Some prescribers shorten the early rungs for someone arriving from a full semaglutide dose; that is clinical judgment, and it is exactly the conversation to have explicitly. The dosage chart shows both ladders side by side, including which Zepbound rungs are maintenance doses and which are titration steps.

Timing the switch week

Common practice is clean: the first tirzepatide dose lands on the day the next semaglutide dose would have been due. No gap, no overlap, the weekly rhythm unbroken. Underneath that neat schedule the pharmacology is a crossfade: semaglutide's 7-day half-life means it fades over weeks while tirzepatide builds, and the washout calculator will draw the leaving half of that picture. The label-facts version of missed timing, including the 72-hour minimum between tirzepatide doses, is in the missed dose guide.

Expect the in-between weeks and log them. The most common switching story: the first two to four weeks at 2.5 mg feel lighter than the old maintenance dose. Appetite shows up earlier, food noise murmurs, and the scale may drift a pound or two. This is the gap between ladders, not the new drug failing. Write down what changes and when; if the drift continues past the first escalations, that record turns a vague worry into a specific prescriber conversation.

What to ask before the first new pen

  • How fast do you plan to move me up the ladder, given the dose I am coming from?
  • Which rung are we treating as the destination, and what decides it?
  • If my insurance approved this switch, what happens at the next formulary review?
  • If the first weeks feel under-dosed, do I call, or ride it out to the schedule?
  • If this does not go well, what does switching back look like?

Switching drugs? Ellie keeps the thread.

Ellie tracks your doses across both medications, models the crossfade weeks, and flags the drift that matters from the noise that does not.

Get Ellie free on the App Store

Frequently asked questions

Is there an equivalent Zepbound dose for my Ozempic or Wegovy dose?

No official equivalence exists, and there is a real reason: they are different molecules hitting different receptor combinations (semaglutide is GLP-1 only; tirzepatide adds GIP). The Zepbound label starts everyone at 2.5 mg regardless of prior semaglutide dose, and escalation from there is tolerability-driven. Some prescribers use clinical judgment to move faster up the ladder after a switch; that is their call to make, not a chart to look up.

Do I need a washout period between semaglutide and tirzepatide?

The labels do not require one, and common practice is to give the first tirzepatide dose when the next semaglutide dose would have been due, so the weekly rhythm continues unbroken. Both drugs take weeks to fully clear regardless (the washout calculator draws the overlap), so the transition is a crossfade, not a hard cut. The exact timing is a prescriber decision.

Will I lose more weight on Zepbound than on Ozempic or Wegovy?

On average, the head-to-head trial says yes: in SURMOUNT-5, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. But averages are not individuals: plenty of people respond better to semaglutide than the mean suggests, and someone maintaining well at their current weight has no arithmetic reason to switch. The strongest cases for switching are a true stall at the top of the semaglutide ladder, tolerability trouble, or insurance forcing the issue.

What does switching feel like in the first weeks?

Commonly reported and mechanically plausible: the first weeks at 2.5 mg can feel lighter than a full semaglutide maintenance dose, with appetite and food noise creeping up while the old drug fades and the new ladder climbs. Some people also re-experience escalation-style gut effects as the new molecule arrives. Neither means the switch failed; it means you are between ladders. Formal data on the transition window specifically is thin, so treat this as reported pattern rather than established timeline.

Can I switch back if Zepbound does not work for me?

Yes, switching in either direction happens and the same logic applies in reverse: no equivalence table, prescriber-guided restart on the semaglutide ladder, timing on the weekly rhythm. Keep notes on doses, dates and how you felt through the first switch; that record is the most useful thing you can hand a prescriber before a second one.

Sources

  • SURMOUNT-5: Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (72 weeks, head to head). N Engl J Med, 2025.
  • SURMOUNT-1: Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med, 2022.
  • Zepbound prescribing information: Zepbound (tirzepatide) full prescribing information, via DailyMed (NIH).
  • Ozempic prescribing information: Ozempic (semaglutide) full prescribing information, via DailyMed (NIH).
  • Wegovy prescribing information: Wegovy (semaglutide) full prescribing information, via DailyMed (NIH).
  • Switch timing conventions (first tirzepatide dose on the next scheduled semaglutide day) and transition-week experiences reflect common clinical practice and community reports; the transition window itself has little published study.

Linked citations open on PubMed or DailyMed, both run by the US National Institutes of Health. Where a claim on this page comes from reporting or clinical commentary we could not resolve to a stable public record, it is listed above without a link rather than pointed at an approximation.